Search Result

Results for "

xenograft.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (1) Acetyl-CoA Carboxylase (1) ACSL Family (2) Acyltransferase (2) ADC Antibody (7) ADC Payload (1) Adenosine Receptor (2) Adrenergic Receptor (3) Akt (60) Aldose Reductase (1) Amino acid Transporter (1) Aminoacyl-tRNA Synthetase (1) Aminopeptidase (2) Aminotransferases (Transaminases) (1) AMPK (6) Anaplastic lymphoma kinase (ALK) (10) Androgen Receptor (28) Annexin A (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (9) Antifolate (2) Apoptosis (335) ASCT (1) ASK1 (1) Atg8/LC3 (6) ATM/ATR (4) ATP Synthase (2) ATP-binding cassette (ABC) transporters (1) Aurora Kinase (12) AUTACs (1) Autophagy (37) Bacterial (7) Bcl-2 Family (41) BCL6 (3) Bcr-Abl (5) BCRP (3) Beclin1 (2) Biochemical Assay Reagents (2) BMI1 (1) Bombesin Receptor (1) BRK (1) Btk (12) c-Fms (1) c-Kit (3) c-Met/HGFR (8) c-Myc (17) Cadherin (4) Calcium Channel (3) CaMK (4) Cannabinoid Receptor (1) Carbonic Anhydrase (2) Casein Kinase (2) Caspase (61) Cathepsin (1) CCR (1) CD19 (1) CD20 (1) CD3 (4) CD38 (2) CD47 (3) CDK (52) Ceramidase (2) Checkpoint Kinase (Chk) (6) Choline Kinase (2) Cholinesterase (ChE) (1) Claudin (1) ClpP (3) Complement System (5) Constitutive Androstane Receptor (1) COX (2) CRAC Channel (2) CTLA-4 (2) Cuproptosis (1) CXCR (3) Cyclophilin (1) Cytochrome P450 (8) Deubiquitinase (4) Dihydroorotate Dehydrogenase (1) Discoidin Domain Receptor (1) DNA Alkylator/Crosslinker (4) DNA Glycosylase (1) DNA Methyltransferase (5) DNA-PK (1) DNA/RNA Synthesis (41) Dopamine Receptor (3) Drug Derivative (12) Drug Intermediate (3) Drug Isomer (1) Drug-Linker Conjugates for ADC (7) E1/E2/E3 Enzyme (9) E3 Ligase Ligand-Linker Conjugates (2) EBV (1) EGFR (53) Emopamil Binding Protein (1) Endogenous Metabolite (4) Enolase (1) Environmental Pollutants (2) Ephrin Receptor (2) Epigenetic Reader Domain (29) ERK (45) Estrogen Receptor/ERR (14) Eukaryotic Initiation Factor (eIF) (4) FABP (1) FAK (11) FAP (1) Fat Mass and Obesity-associated Protein (FTO) (3) Fatty Acid Synthase (FASN) (2) Fc Receptor (FcR) (2) Ferroptosis (18) FGFR (21) FLAP (1) FLT3 (18) Fluorescent Dye (2) Free Fatty Acid Receptor (1) FXR (1) G Protein-coupled Receptor Kinase (GRK) (1) G-quadruplex (3) GLP Receptor (1) GLUT (3) Glutaminase (2) Glutathione Peroxidase (7) Glutathione S-transferase (1) Glycoprotein VI (2) Glycosidase (1) GnRH Receptor (1) HDAC (23) Herbicide (1) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (5) Hippo (MST) (3) Histone Acetyltransferase (13) Histone Demethylase (4) Histone Methyltransferase (20) HIV (2) HOXA (1) HSP (14) Hsp-targeting Chimeras (1) HSV (1) HyT (1) IAP (3) IFNAR (5) IGF-1R (2) IKK (5) IKZF Family (3) Indoleamine 2,3-Dioxygenase (IDO) (3) Influenza Virus (1) Insulin Receptor (2) Integrin (7) Interleukin Related (16) IRAK (2) Isotope-Labeled Compounds (3) Itk (1) JAK (15) JNK (7) Kallikrein (1) Keap1-Nrf2 (2) KLF (1) Lactate Dehydrogenase (1) LAG-3 (1) Lipase (1) Liposome (1) LPL Receptor (4) MALT1 (2) MAPKAPK2 (MK2) (1) MASTL (1) MDM-2/p53 (28) MEK (10) Mesothelin (1) MetAP (1) Methionine Adenosyltransferase (MAT) (4) MHC (1) Microtubule/Tubulin (45) Mitochondrial Metabolism (13) Mitophagy (2) Mitosis (5) Mixed Lineage Kinase (3) MMP (9) MNK (6) Molecular Glues (12) Monocarboxylate Transporter (1) Mps1 (5) mTOR (23) Mucin (2) Na+/Ca2+ Exchanger (2) nAChR (2) NAMPT (7) Necroptosis (5) Nectin-4 (1) NEDD8-activating Enzyme (4) Neurotensin Receptor (2) NF-κB (10) NO Synthase (1) NOD-like Receptor (NLR) (1) Notch (5) NTPDase (1) Nuclear Hormone Receptor 4A/NR4A (2) Nucleoside Antimetabolite/Analog (2) Oct3/4 (2) Organoid (2) Orphan Nuclear Receptor (1) Oxidative Phosphorylation (3) P-glycoprotein (8) p38 MAPK (25) p62 (7) p97 (3) PAK (5) PANoptosis (1) Paraptosis (1) Parasite (3) PARP (36) PD-1/PD-L1 (3) PDGFR (10) PDK-1 (1) Peptide-Drug Conjugates (PDCs) (2) PERK (10) PGE synthase (1) Phosphatase (7) Phosphodiesterase (PDE) (1) Phosphoglycerate Kinase (PGK) (2) Photosensitizer (1) PI3K (36) PI4K (2) PIKfyve (1) Pim (4) PKA (1) PKC (2) Polo-like Kinase (PLK) (8) Porcupine (1) Potassium Channel (1) PPAR (1) Progesterone Receptor (1) PROTACs (78) Proteasome (4) PSMA (6) Pyk2 (2) Pyroptosis (4) Pyruvate Kinase (1) Quinone Reductase (3) Radionuclide-Drug Conjugates (RDCs) (5) Raf (9) RAR/RXR (2) Ras (31) Reactive Oxygen Species (ROS) (51) Reference Standards (19) RET (10) Ribosomal S6 Kinase (RSK) (3) RIO Kinase (2) RIP kinase (1) ROCK (3) ROR (2) ROS Kinase (5) Salt-inducible Kinase (SIK) (1) SARS-CoV (4) SDCBP (1) Ser/Thr Protease (2) SGK (1) SHMT (1) SHP1 (1) SHP2 (5) Sialyltransferase (2) Sigma Receptor (2) Sirtuin (3) Small Interfering RNA (siRNA) (2) SOD (1) SOS1 (3) Src (6) SRPK (1) STAT (37) Stearoyl-CoA Desaturase (SCD) (2) STING (1) Survivin (5) SWI/SNF Complex (4) Syk (3) TAM Receptor (6) Telomerase (3) TGF-beta/Smad (4) TGF-β Receptor (4) Thymidylate Synthase (2) Tie (1) TNF Receptor (13) TNK1 (1) Toll-like Receptor (TLR) (4) Topoisomerase (13) Transmembrane Glycoprotein (12) Trk Receptor (8) TROP2 (1) TRP Channel (4) TrxR (1) Tyrosinase (1) Tyrosine Hydroxylase (2) VDAC (1) VEGFR (19) WDR5 (1) Wee1 (5) Wnt (8) YAP (13) Zinc Finger Protein (1) β-catenin (8)
By Research Areas:	Cancer (945) Cardiovascular Disease (10) Endocrinology (8) Infection (15) Inflammation/Immunology (55) Metabolic Disease (12) Neurological Disease (25)
Click Chemistry:	PROTAC Synthesis (5) Azide (2) Alkynes (9)
Oligonucleotides:	Aptamers (3) Antisense Oligonucleotides (2)

954

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-101120

666-15 55+ Cited Publications	Epigenetic Reader Domain	Cancer
666-15 is a potent and selective CREB inhibitor with an IC₅₀ of 81 nM. 666-15 suppresses tumor growth in a breast cancer xenograft model .

HY-148517

AZD0095 4 Publications Verification	Monocarboxylate Transporter	Cancer
AZD0095 is a selective and orally active MCT4 inhibitor (IC₅₀: 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205) .

HY-173637

AZD0022	Ras	Cancer
AZD0022 is a selective and orally active KRAS ^G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .

HY-19981

Derazantinib 3 Publications Verification ARQ-087	FGFR	Cancer
Derazantinib (ARQ-087) is an ATP competitive and orally activeFGFR inhibitor (IC₅₀s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3 nM). Derazantinib inhibits FGFR phosphorylation. Derazantinib inhibits tumor growth in multiple xenograft models .

HY-P99160

Labetuzumab hMN14	Transmembrane Glycoprotein	Cancer
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .

HY-120394

TVB-3166 10+ Cited Publications	Fatty Acid Synthase (FASN) Apoptosis	Cancer
TVB-3166 is an orally-available, reversible, and selective fatty acid synthase (FASN) inhibitor with IC₅₀s of 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively. TVB-3166 induces apoptosis, and inhibits in-vivo xenograft tumor growth .

HY-132166

Velzatinib 1 Publications Verification M4205; IDRX-42	c-Kit PDGFR c-Fms FLT3 Src	Cancer
Velzatinib (M4205) is a multi-target inhibitor for PDGFRB, PDGFRA, CSF1R, c-Kit, FLT3, and LCK, with an IC₅₀s of 2.6, 50, 5.5, 44, 141 and 141 nM, respectively. Velzatinib exhibits antitumor efficacy in xenograft mouse models .

HY-P99849

Depatuxizumab ABT-806	EGFR	Cancer
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .

HY-15766

GNE-617 5+ Cited Publications	NAMPT	Metabolic Disease Cancer
GNE-617 is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC₅₀ of 5 nM and exhibits efficacy in xenograft models of cancer.

HY-15323

PRT062607 Hydrochloride 4 Publications Verification P505-15 Hydrochloride	Syk Mixed Lineage Kinase PAK Pyk2 FAK Apoptosis Src	Cancer
PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC₅₀: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models .

HY-161952

Sitneprotafib JAB-3312	SHP2	Cancer
Sitneprotafib (JAB-3312) is an orally effective anticancer phosphatase SHP2 inhibitor (IC₅₀: 1.9 nM) with anti-cancer activity. Sitneprotafib has good tolerability and significantly induced tumor regression in a KYSE-520 mouse xenograft model .

HY-124628

IPI-9119 2 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC₅₀ of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models .

HY-159579

CW-3308	PROTACs Epigenetic Reader Domain	Cancer
CW-3308 is an orally active BRD9 PROTAC degrader with an DC₅₀ of 92 nM. CW-3308 forms a ternary complex with BRD9 and cereblon to mediate BRD9 degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces BRD9 protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors .

HY-136538

LQZ-7I	Survivin	Cancer
LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors .

HY-156715

MASTL-IN-1	MASTL	Cancer
MASTL-IN-1 is a selective and orally active MASTL inhibitor with a K_i <0.03 nM. MASTL-IN-1 inhibits phosphorylation of ENSA and inhibits proliferation in cancer cells. MASTL-IN-1 induces tumor growth inhibition and stasis in pancreatic cancer xenograft models .

HY-P99237

Sofituzumab MMUC 1206A	Mucin	Cancer
Sofituzumab (MMUC 1206A) is an anti-MUC16 antibody with a K_d of 0.3-0.9 nM. Sofituzumab can bind multiple adjacent antibody molecules to the repeat sequences of the same MUC16 molecule. Sofituzumab exhibits no anti-tumor activity in the HPAC pancreatic adenocarcinoma xenograft model .

HY-136447

ASP4132 1 Publications Verification	AMPK	Cancer
ASP4132 is an orally active, potent AMPK activator with an EC₅₀ of 18 nM. ASP4132 has anti-cancer activity and makes tumor regression in breast cancer xenograft mouse models .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-148422

Rohinitib 1 Publications Verification	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

HY-156111

ARD-1676 1 Publications Verification	PROTACs Androgen Receptor	Cancer
ARD-1676 is an orally available androgen receptor (AR) PROTAC degrader, consisting of AR ligand and cereblon ligand. ARD-1676 has AR-degrading activity in vitro and in vivo and inhibits VCaP tumor growth in mouse xenograft tumor models .

HY-153364

FTX-6746	PPAR	Cancer
FTX-6746 is an orally active PPARG inhibitor. FTX-6746 shows potent tumor inhibition in mouse xenograft models .

HY-153521

CCT374705	BCL6	Cancer
CCT374705 is an orally active BCL6 inhibitor (IC₅₀ = 4.8 nM) with potent antiproliferative effects in vitro. CCT374705 effectively inhibits tumor growth in a lymphoma xenograft mouse model .

HY-155079

DZD1516	EGFR	Cancer
DZD1516 is a potent and selective HER2 inhibitor (IC₅₀=0.56 nM) with good blood-brain permeability. DZD1516 exhibits antitumor activity in CNS and subcutaneous xenograft mouse models .

HY-147208

MSC-4106	YAP	Cancer
MSC-4106 is an orally active and potent inhibitor of YAP/TAZ-TEAD. MSC-4106 inhibits TEAD1 or TEAD3 auto-palmitoylation and shows inhibitory effect on NCI-H226 tumor xenograft model .

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts .

HY-117366

PS432	PKC	Cancer
PS432 is a PKC inhibitor with IC₅₀s of 16.9 μM (PKC_ι) and 18.5 μM (PKC_ζ), respectively. PS432 effectively inhibits the proliferation of non-small cell lung cancer cells (NSCLCs) and tumor growth in mouse xenograft models .

HY-16405

PR-104	DNA Alkylator/Crosslinker	Cancer
PR-104 is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104, as a nitrogen mustard pre-proagent, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A .

HY-169779

PTX80	p62	Cancer
PTX80 is an antagonist of p62 with an IC₅₀ value of 31.18 nM. PTX80 reduces tumor volume in an HCT116 colorectal cancer mouse xenograft model .

HY-147402A

Taragarestrant meglumine D-0502 meglumine	Estrogen Receptor/ERR	Cancer
Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant meglumine shows potent activity in various ER+ breast cancer cell lines and xenograft models .

HY-131446

Chk1-IN-5 1 Publications Verification	Checkpoint Kinase (Chk)	Cancer
Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model .

HY-163133

PIKfyve-IN-3	PIKfyve	Cancer
PIKfyve-IN-3 (compound L22) has a remarkable interaction with PIKfyve kinase with a K_d value of 0.47 nM. PIKfyve-IN-3 has oral activity. PIKfyve-IN-3 inhibits tumor growth in a HeLa xenograft model .

HY-110201

Estrogen receptor modulator 1	Estrogen Receptor/ERR	Cancer
Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC₅₀ of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors .

HY-163743

SIC-19	Salt-inducible Kinase (SIK)	Cancer
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .

HY-156681A

(S)-Tersolisib (S)-STX-478; (S)-STX-478-101; (S)-LY4064809	PI3K	Cancer
(S)-STX-478 is the S-enantiomer of STX-478. STX-478 is a selective inhibitor of PI3Kα mutants, preventing metabolic dysfunction and demonstrating antitumor activity in xenograft mouse models with PI3Kα mutant tumors .

HY-N7694

Isotoosendanin 1 Publications Verification	TGF-β Receptor JAK STAT Apoptosis	Inflammation/Immunology Cancer
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-176772

QHL-1618	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
QHL-1618 is a tumor microenvironment-activated drug conjugate. QHL-1618 inhibits the tumor growth in various tumor models, such as HT-1080 xenograft, CT-26 xenograft .

HY-172970

HQY1428	CDK DNA/RNA Synthesis Apoptosis	Cancer
HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .

HY-15324

PRT062607 acetate 4 Publications Verification P505-15 acetate; PRT-2607 acetate; BIIB-057 acetate	Syk Src Mixed Lineage Kinase PAK Pyk2 FAK Apoptosis	Cancer
PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC₅₀: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models . .

HY-158006

SDX-7539	MetAP	Cancer
SDX-7539 is a selective inhibitor for Methionine aminopeptidase type 2 (MetAP2). SDX-7539 inhibits proliferarion of HUVECs with an IC₅₀ of 120 μM. SDX-7539 exhibits antitumor activity in NSCLC xenograft athymic nude mice .

HY-162477

TS-24	Cathepsin Apoptosis	Cancer
TS-24 is an inhibitor for cathepsin S, with an IC₅₀ of 4.3 μM. TS-24 exhibits radiosensitizing activity in wild type breast cancer susceptibility gene 1 (BRCA1) and in TNBC xenograft mice model, through induction of apoptosis .

HY-168950

ANXA3 degrader 1	Annexin A	Cancer
ANXA3 degrader 1 (Compound 18a5) is a highly selective ANXA3 degrader with cancer cell inhibition activity. ANXA3 degrader 1 displays excellent inhibitory effect in a triple-negative breast cancer (TNBC) tumor xenograft model (TGI=96%) .

HY-176498

NBM-T-BMX-OS01 BMX	VEGFR FAK Akt PERK	Cancer
NBM-T-BMX-OS01 is an Osthole (HY-N0054) derivative. NBM-T-BMX-OS01 inhibits the phosphorylation of VEGFR2, FAK, Akt and ERK. NBM-T-BMX-OS01 has anti-angiogenic activity. NBM-T-BMX-OS01 has anti-cancer activity against colorectal cancer .

HY-15766A

GNE-617 hydrochloride 5+ Cited Publications	NAMPT	Cancer
GNE-617 hydrochloride is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC₅₀ of 5 nM and exhibits efficacy in xenograft models of cancer.

HY-14375

CB 300919	NAMPT	Cancer
CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC₅₀ value of 2 nM in human CH1 ovarian tumor xenograft . CB 300919 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147402

Taragarestrant D-0502	Estrogen Receptor/ERR	Cancer
Taragarestrant (D-0502) is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant shows potent activity in various ER+ breast cancer cell lines and xenograft models .

HY-173637A

(S)-AZD0022	Ras	Cancer
(S)-AZD0022 is an isomer of AZD0022, AZD0022 is a selective and orally active KRAS ^G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .

HY-175502

MGD-22	Molecular Glues IKZF Family Apoptosis	Cancer
MGD-22, a molecular glue, is an orally active IKZF1/2/3 degrader with DC₅₀ values of 8.33 nM, 9.91 nM, and 5.74 nM, respectively. MGD-22 exhibits extremely potent anti-proliferative activity against diverse hematological cancer cells. MGD-22 induces apoptosis in cancer cells. MGD-22 demonstrates potent anti-tumor efficacy in mice bearing NCI-H929 xenografts or WSU-DLCL-2 xenografts. MGD-22 can be used for the study of hematological cancers, including multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL) .

HY-W369099

HJC0152 free base	STAT Apoptosis	Cancer
HJC0152 (free base) is an orally active and potent inhibitor of STAT3. HJC0152 (free base) inhibits cell cycle progression and induces apoptosis. HJC0152 (free base) significantly suppresses MDA-MB-231 xenograft tumor growth in mice .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613); EP-100	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-126730

Rubratoxin A	Phosphatase	Cancer
Rubratoxin A is a natural mycotoxin and competitive inhibitor of protein phosphatase 2A (PP2A) with an IC₅₀ of 170 nM. Rubratoxin A causes suppression of tumor metastasis and reduction of primary tumor volume in mouse xenografts .

Cat. No.	상품명	Type

HY-164992

Trastuzumab vedotin

2 Publications Verification

MRG002; Trastuzumab MMAE

Fluorescent Dyes

Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a K_d of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .

HY-177434

Precemtabart tocentecan

Precem-TcT; M 9140

Fluorescent Dyes

Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .

HY-D2062

ATTO 740 NHS ester

Fluorescent Dyes

ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .

HY-159642G

Dabogratinib

TYRA-300

Fluorescent Dyes

Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

HY-D2620

CAR-2	Fluorescent Dyes
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC₅₀ of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models .

HY-158726

Complex 3

Fluorescent Dyes

Complex 3 is a fluorescent dithiocarbazate-copper complex with anticancer activity, which localizes to mitochondria. Complex 3 displays excitation/emission maxima of 455-495/535 nm, respectively. Complex 3 inhibits the growth of BxPC-3, AsPC-1, PANC-1, and WI38 pancreatic cancer cells with IC₅₀ values of 0.74, 0.41, 0.62, and 2.06 µM, respectively. Complex 3 induces lipid peroxidation and mitochondrial rupture and shrinkage in AsPC-1 cells. Complex 3 also induces mitochondrial apoptosis and cytokine-cytokine receptor interaction dysfunction in AsPC-1 cells. Complex 3 reduces tumor volume in an AsPC-1 mouse xenograft model .

HY-D3353

PSMA-SulfoCy7

Fluorescent Dyes

PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a K_i of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies .

Cat. No.	상품명	Type

HY-159642G

Dabogratinib

TYRA-300

Biochemical Assay Reagents

Cat. No.	상품명	Target	Research Area

HY-P10925

Zolucatetide FOG-001; I-66	β-catenin	Cancer
Zolucatetide (FOG-001;I-66) is a potent β-catenin inhibitor with an IC₅₀ of <50 nM. Zolucatetide can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. Zolucatetide inhibits cell proliferation and induces cell cycle arrest in target cells. Zolucatetide exhibits anti-tumor efficacy in mice bearing COLO320DM colon cancer cell (with APC, TP53 mutations) xenografts. Zolucatetide can be used for the study of colon cancer .

HY-156002

LUNA18 Paluratide	Ras ERK	Cancer
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .

HY-164388

Z-VAD Maximum Cited Publications 19 Publications Verification	Caspase Apoptosis Autophagy Necroptosis	Cardiovascular Disease Cancer
Z-VAD is an irreversible, broad-spectrum pan-caspase inhibitor that can inhibit a variety of caspases including caspase-3, -6, -7, -8, -9, etc. (with a weaker inhibitory effect on caspase-2). Z-VAD can block apoptosis signaling pathways, induce autophagy and necrosis in tumor cells, and has anti-angiogenic activity. Z-VAD can enhance the sensitivity of breast cancer and lung cancer cells to radiotherapy in vitro and in vivo, and prolong the growth delay of tumor xenograft models. Z-VAD is well tolerated and is mainly used in research related to cancer radiosensitization and cell death pathway regulation .

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1925A

GO-203 TFA 2 Publications Verification	PI3K Reactive Oxygen Species (ROS) Apoptosis	Cancer
GO-203 TFA is a potent MUC1-C oncoprotein inhibitor. GO-203 TFA is an all D-amino acid peptide that consists of a poly-R transduction domain linked to a CQCRRKN motif that binds to the MUC1-C cytoplasmic tail and blocks MUC1-C homodimerization. GO-203 TFA downregulates TIGAR (TP53-induced glycolysis and apoptosis regulator) protein synthesis by inhibiting the PI3K-AKT-S6K1 pathway. GO-203 TFA induces the production of ROS and loss of mitochondrial transmembrane potential. GO-203 TFA inhibits the growth of colon cancer cells in vitro and as xenografts in nude mice .

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-P10816

PACE4 Inhibitory peptide C23 Ac-(DLeu)LLLRVK-Amba	Bacterial	Infection Cancer
PACE4 Inhibitory peptide C23 (Compound C23; Ac-(DLeu)LLLRVK-Amba)), a potent peptidomimetic inhibitor, is a PACE4 inhibitor. PACE4 Inhibitory peptide C23e shows antiproliferative effects against PCa cell lines (K_i = 5 nM; IC₅₀ = 25 and 40 μM for DU145 and LNCaP, respectively). PACE4 Inhibitory peptide C23 also blocks tumor growth in vivo in LNCaP xenograft-bearing mice .

HY-P11228

FPP29	PROTACs Apoptosis DNA/RNA Synthesis	Cancer
FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)) .

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613); EP-100	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-P1651B

SOR-C13 acetate 1 Publications Verification	TRP Channel	Cancer
SOR-C13 acetate is the acetate salt form of SOR-C13 (HY-P1651). SOR-C13 acetate is an antagonist for transient receptor potential vanilloid 6 (TRPV 6), with an IC₅₀ of 14 nM. SOR-C13 acetate inhibits tumor growth in SKOV-3 xenograft mouse model .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-178489

BGC1614	Nectin-4	Cancer
BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an K_D of 3.859 × 10 ^-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .

HY-P10994

Eps8 peptide 327 Eps8(327-335)	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
Eps8 peptide 327 is an HLA-A2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis* and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-13589

Cemadotin LU103793 free base	Microtubule/Tubulin Mitosis	Cancer
Cemadotin (LU103793) is a water-soluble synthetic analogue of Dolastatin 15 (HY-P1126) that inhibits cell proliferation in vitro and the growth of tumor xenografts in mice. Cemadotin blocks cells at mitosis, and exhibits K_i value of 1 μM for inhibiting tubulin. Cemadotin can be used to research anticancer .

HY-P10793

Cyclic(YCDGFYACYMDV)	EGFR Apoptosis	Cancer
Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis). The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model .

HY-P10992

YVPGP	PI3K Akt mTOR Caspase Apoptosis Bcl-2 Family	Cancer
YVPGP is an oligopeptide exacted from Anthopleura anjunae. YVPGP has a significant antitumor activity by mediating PI3K/AKT/mTOR signaling pathway. YVPGP arrests DU-145 cells in the S phase and induces apoptosis via mitochondrial and death receptor pathways (caspase3, 7, 8, 9). YVPGP effectively inhibits tumor growth in DU-145 xenografts mice model, promising for prostate cancer research .

HY-P11076

CP-EPS8-NLS	Complement System	Cancer
CP-EPS8-NLS is a peptide with anti-AML property. CP-EPS8-NLS interferes with EPS8-associated signaling and exerts anti-AML activity in various AML cell types. CP-EPS8-NLS has potent antitumor activity in xenograft tumor models. CP-EPS8-NLS downregulates EPS8 expression and its downstream pathway .

HY-P10988

LVTX-8	Apoptosis MDM-2/p53 Integrin	Cancer
LVTX-8 is a peptide toxin, exacted from Lycosa vittata. LVTX-8 has potent anticancer and and anti-metastasis activities towards lung cancer with strong cytotoxicity. LVTX-8 significantly induces apoptosis and inhibits the proliferation, invasion and migration of lung cancer cells through P53 hypoxia pathways and integrin signaling. LVTX-8 significantly inhibits the tumor growth and metastasis in A549/H460 xenograft mice model .

HY-P10775A

BT1769 acetate	MMP	Cancer
BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a K_d value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research .

HY-P5520

GB-6	Bombesin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects .

HY-P11405

[D-Arg1,D-Trp5,7,9,Leu11]-Substance P	Neurotensin Receptor	Neurological Disease Cancer
[D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is a potent inhibitor of cell growth in small cell lung cancer (SCLC). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is also a neuropeptide antagonist, capable of blocking colony formation stimulated by various neuropeptides (including vasopressin and bradykinin). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the mobilization of Ca ²⁺ and the activation of mitogen-activated protein kinases induced by vasopressin or bradykinin. [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the growth of H-69 xenograft tumors in nude mice .

HY-13589A

Cemadotin hydrochloride LU103793 hydrochloride	Microtubule/Tubulin Mitosis	Cancer
Cemadotin (LU103793) hydrochloride is a water-soluble synthetic analogue of Dolastatin 15 (HY-P1126) that inhibits cell proliferation in vitro and the growth of tumor xenografts in mice. Cemadotin hydrochloride blocks cells at mitosis, and exhibits K_i value of 1 μM for inhibiting tubulin. Cemadotin hydrochloride can be used to research anticancer .

HY-P10788

CK3 peptide	Complement System	Cancer
CK3 peptide is an NRP-1 targeting peptide with the amino acid sequence CLKADKAKC. The CK3 peptide specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging show significant accumulation of CK3 peptide in xenograft tumors in nude mice. CK3 peptide can be used for molecular imaging studies of breast cancer.

HY-P10995

TAT-327	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
TAT-327 is cell-penetrating peptide. TAT-327 selectively inserts into cancer cell membranes and shows potent antitumor activity. TAT-327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. TAT-327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-P10744

BQ7859	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10819

S9-CMC1 TFA	Histone Demethylase Apoptosis	Cancer
S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits LSD1 activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

HY-P10792A

HYNIC-H6F	EGFR	Cancer
HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC₅₀ = 11 nM). HYNIC-H6F accumulates in HER2-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in HER2-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of HER2-positive breast cancer in mouse models and allows evaluation of HER2 expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research .

HY-P11594

JMV 7490	Neurotensin Receptor	Cancer
JMV 7490 is a highly potent and highly hydrophilic neurotensin receptor NTS₁ probe that can be successfully labeled with ⁶⁸Ga and ¹¹¹In. JMV 7490 acts as an efflux inhibitor to reduce its efflux in NTS₁-positive cancer cells; it also serves as an internalization inducer and is efficiently and continuously internalized by NTS₁-positive cancer cells. ¹¹¹In-radiolabeled JMV 7490 shows persistent uptake in NTS₁-positive xenografts in nude mice, but no significant uptake in NTS₁-negative xenografts. JMV 7490 can be used for in vivo tracer applications of NTS1-positive tumors and supports related research on colorectal cancer .

HY-P11599

NOTA-SP2A-FAPT	FAP	Cancer
NOTA-SP2A-FAPT is a fibroblast activation protein (FAP) ligand. NOTA-SP2A-FAPT can be adiolabeled and exhibits rapid renal excretion with fast kidney tissue clearance, accumulates rapidly in and retains high levels in FAP-positive tumor xenografts to enable clear tumor visualization. NOTA-SP2A-FAPT can be used as a tracer of cancer .

HY-P11760

HER2-targeted peptide H10	EGFR	Cancer
HER2-targeted peptide H10 is a HER2-targeting peptide with a K_d value of 30.4 nM. HER2-targeted peptide H10 specifically accumulates in HER2-positive tumor tissues of xenograft mice, when conjugated with nanoparticles. HER2-targeted peptide H10 can be used for studies related to HER2-positive breast cancer .

HY-180989

PROTAC PLK1 Degrader-2	PROTACs Polo-like Kinase (PLK) Apoptosis	Cancer
PROTAC PLK1 Degrader-2 (Compound NC1) is a PLK1 PROTAC degrader with an K_d of 6.06 μM. PROTAC PLK1 Degrader-2 significantly inhibits the proliferation of HeLa cells, induces cell cycle arrest and apoptosis. PROTAC PLK1 Degrader-2 exhibits significant anti-tumor activity in a HeLa cell xenograft tumor mouse model. PROTAC PLK1 Degrader-2 can be used for the study of cervical cancer.

HY-P11756

P-LPK	ASCT	Cancer
P-LPK is a dodecapeptide that specifically targets SLC1A5, which is highly expressed on the membrane of colorectal cancer cells, with a K_d value of 1.19 μM. P-LPK has no intrinsic cell proliferation regulatory activity. Gallium-68-labeled P-LPK selectively accumulates at colorectal cancer tumor sites in xenograft mouse models. P-LPK can serve as a targeted carrier to deliver Camptothecin (HY-16560) to colorectal cancer cells, forming the conjugate P-LPK-CPT. P-LPK can be used in the research of colorectal cancer .

HY-P11618

10P3Me	Glycoprotein VI	Cancer
10P3Me is a Glypican-3 (GPC3)-targeting probe with a K_a of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .

Cat. No.	상품명	Target	Research Area	Image

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P990673

Vandortuzumab DSTP-3086S Antibody; RG-7450 Antibody	ADC Antibody Transmembrane Glycoprotein Mitosis	Cancer
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99160

Labetuzumab hMN14	Transmembrane Glycoprotein	Cancer
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .

HY-P990148

Anti-Mouse VEGF-A Antibody (2G11-2A05) 1 Publications Verification	VEGFR	Cancer
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a κ type antibody inhibitor, tragrting to mouse VEGF-A with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .

HY-P99849

Depatuxizumab ABT-806	EGFR	Cancer
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .

HY-P9964

Necitumumab 11F8; IMC-11F8; LY3012211	EGFR	Cancer
Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P990792

Anti-Mouse CD4 Antibody (GK1.5)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4 ⁺ T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682) .

HY-P99364

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

HY-P991558

RO-5429083 RG-7356	Transmembrane Glycoprotein	Cancer
RO-5429083 (RG-7356) is a humanized monoclonal antibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia .

HY-P991577

DS-8895 DS-8895A	Ephrin Receptor	Cancer
DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with ⁸⁹Zr, ¹¹¹In, or ¹²⁵I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P9992

Pelgifatamab BAY-2315497; PSMA-TTC	PSMA Apoptosis	Cancer
Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC₅₀ of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .

HY-P99237

Sofituzumab MMUC 1206A	Mucin	Cancer
Sofituzumab (MMUC 1206A) is an anti-MUC16 antibody with a K_d of 0.3-0.9 nM. Sofituzumab can bind multiple adjacent antibody molecules to the repeat sequences of the same MUC16 molecule. Sofituzumab exhibits no anti-tumor activity in the HPAC pancreatic adenocarcinoma xenograft model .

HY-P99272

Ulocuplumab 1 Publications Verification BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P991669

IGN523 AML-01	Caspase Apoptosis	Cancer
IGN523 is an anti-CD98 antibody (hCD98, K_D = 0.55 nM). IGN523 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activity, lysosomal membrane permeabilization, and inhibition of essential amino acid transport, ultimately leading to caspase-3 and caspase-7-mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in multiple tumor xenograft models. IGN523 is useful in the research of non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and other cancers. .

HY-P99943

Erfonrilimab KN-046	PD-1/PD-L1 CTLA-4	Cancer
Erfonrilimab (KN-046) is a monoclonal antibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.

HY-P991584

HuGAL-FR21	FGFR	Cancer
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-P99320

Tarextumab OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody	Notch	Cancer
Tarextumab (OMP-59R5) is a cross-reactive, fully human IgG2 antibody that selectively inhibits Notch2 and Notch3 signaling. Tarextumab demonstrates broad-spectrum antitumor efficacy in xenograft models of epithelial tumors. Tarextumab can be used for the study of pancreatic cancer .

HY-P99492

Cantuzumab mertansine SB-408075; huC242-DM1	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-P99744

Modakafusp alfa TAK-573	CD38	Inflammation/Immunology Cancer
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .

HY-P99916

Emirodatamab AMG-427	FLT3 CD3 TNF Receptor	Inflammation/Immunology Cancer
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .

HY-P99148

Anti-Mouse/Rat/Rabbit TNF alpha Antibody (TN3-19.12)	TNF Receptor	Metabolic Disease Inflammation/Immunology
Anti-Mouse TNF alpha Antibody (TN3-19.12) is an anti-mouse TNF alpha IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse TNF alpha Antibody (TN3-19.12) neutralizes cytotoxic activity in supernatants obtained from LNC-8 cells. Anti-Mouse TNF alpha Antibody (TN3-19.12) reduces the symptoms and severity of EAE (experimental allergic encephalomyelitis) in LNC-8 cells xenograft mice models. Anti-Mouse TNF alpha Antibody (TN3-19.12) prevents diabetes in NOD mice. Anti-Mouse TNF alpha Antibody (TN3-19.12) shows apparent radiosensitizing effect in CD2F1 mice .

HY-P99395

Talacotuzumab 1 Publications Verification JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P99922

Encelimab	LAG-3	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .

HY-P99493

Cantuzumab ravtansine 1 Publications Verification IMGN242; huC242-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-P991570

Zaptuzumab AD5-10; oba-01 Antibody	TNF Receptor Apoptosis Caspase Atg8/LC3 Akt Beclin1 JNK	Cancer
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models .

HY-P990068

Perenostobart SRF617	NTPDase	Inflammation/Immunology Cancer
Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC₅₀ values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4 ⁺ T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer .

HY-P99712

Lonigutamab hz208F2-4	IGF-1R Apoptosis ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases .

HY-P990947

Tilatamig AZD9592 Antibody	ADC Antibody EGFR	Cancer
Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) .

HY-P990953

Zubotamig Gen1047	CD3	Cancer
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .

HY-111965

PF-06647263 anti-EFNA4-ADC	Antibody-Drug Conjugates (ADCs) DNA Alkylator/Crosslinker Antibiotic Apoptosis	Cancer
PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody (HY-P991109), ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts .

HY-P991609

ABX-MA1	MMP	Cancer
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

HY-P991057

STI-6643	CD47	Cancer
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 blocks CD47-SIRPα interaction, and enables macrophage-mediated phagocytosis of tumor cells. STI-6643 shows anti-tumor activity in mouse lymphoma xenograft models. STI-6643 can be used for the research of Burkitt's lymphoma, solid tumors, relapsed or refractory tumors, and lymphoma. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991571

GC1118 GC-1118A	EGFR PERK Akt	Cancer
GC1118 (GC-1118A) is a fully human anti-EGFR monoclonal antibody with binding affinity of 0.16 nM (K_D) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer .

HY-P991618

ST2485	Transmembrane Glycoprotein	Cancer
ST2485 is a monoclonal antitenascin antibody. ST2485 shows additivity in tenascin C binding in vitro as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research .

HY-P991448

MDX-1414	Glycoprotein VI	Cancer
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991663

AMG-780	Tie	Cancer
AMG-780 is a fully human IgG2 antibody that targets angiopoietin 1 (Ang1) (IC₅₀ = 4.5 nM) and angiopoietin 2 (Ang2) (IC₅₀ = 0.06 nM). AMG-780 inhibits tumor growth in the Colo205 xenograft mouse model by inhibiting both Ang1 and Ang2. AMG-780 is indicated for the research of cancers such as colon cancer .

HY-P991779

Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19)	EGFR	Cancer
Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) reacts with domain III of human and canine HER2. Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) exerts antitumor activity in mouse oral cancer xenografts. Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .

HY-P991542

GBR-401	CD19	Cancer
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .

HY-P991561

AO-176	CD47	Cancer
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .

HY-P990851

Anti-c-Kit/CD117 Antibody (SR-1)	c-Kit	Inflammation/Immunology Cancer
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human c-Kit/CD117. Anti-c-Kit/CD117 Antibody (SR-1) binds to the extracellular domain of human c-Kit (also known as CD117) and blocks stem cell factor (SCF) binding to CD117. Anti-c-Kit/CD117 Antibody (SR-1) can be used for the researches of cancer and immunology, such as gastrointestinal stromal tumor (GIST) and xenograft .

HY-P991243

MP-RM-1	EGFR Akt	Cancer
MP-RM-1 is an antibody-based, non-competitive ErbB-3 inhibitor with a K_d value of 32.7 nM. MP-RM-1 inhibits both ligand-dependent and ligand-independent ErbB-3 activation, blocks ErbB-2/ErbB-3 heterodimerization, induces ErbB-3 internalization and degradation, and suppresses the phosphorylation of downstream Akt. MP-RM-1 exerts its antagonistic effect through a non-competitive mechanism. MP-RM-1 inhibits tumor growth in melanoma and prostate cancer xenograft models in nude mice and reduces the proliferative activity of tumor cells .

HY-P991547

Anti-CD20 Antibody (mAb 1.5.3)	CD20 Apoptosis	Inflammation/Immunology Cancer
Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies .

HY-P991639

BIW-8962	Apoptosis	Cancer
BIW-8962 is a humanized anti-ganglioside GM2 antibody. BIW-8962 exhibits ADCC/CDC activity against multiple myeloma cells. BIW-8962 demonstrates potent anti-tumor activity in mouse xenograft models. BIW-8962 is indicated for research in myeloma and other cancers .

HY-P991585

MORAb-028	Inhibitory Antibodies	Cancer
MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .

HY-P991233

BAT1006	EGFR	Cancer
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .

Cat. No.	상품명	Category	Target	Chemical Structure

HY-N6972

Cepharanthine Maximum Cited Publications 13 Publications Verification	Infection Alkaloids Stephania cepharantha Hayata Classification of Application Fields Plants Isoquinoline Alkaloids Menispermaceae Inflammation/Immunology Disease Research Fields Stephania japonica (Thunb.) Miers	Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite
Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC₉₀) values of 1.90 and 4.46 μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

HY-N0421

Cinobufagin 5+ Cited Publications Cinobufagine	Animals Classification of Application Fields Disease Research Fields Steroids Source Classification Cancer	Apoptosis
Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .

HY-B0199A

Mycophenolate mofetil hydrochloride 10+ Cited Publications RS 61443 hydrochloride; TM-MMF hydrochloride	Structural Classification Monophenols Classification of Application Fields Phenols Endogenous metabolite Disease Research Fields Source Classification Cancer	Interleukin Related
Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .

HY-120692

Cyclanoline chloride	Alkaloids Structural Classification Cyclea insularis (Makino) Hatusima Plants Isoquinoline Alkaloids Menispermaceae Source Classification	JAK STAT Apoptosis
Cyclanoline chloride is an alkaloid. Cyclanoline chloride can be isolated from Fangji. Cyclanoline (chloride) inhibits the phosphorylation of JAK2 and STAT3, and induces Apoptosis. Cyclanoline chloride suppresses tumor growth in subcutaneous bladder cancer xenograft models of nude mice. Cyclanoline chloride reverses cisplatin resistance in bladder cancer cells and enhances the efficacy of Cisplatin (HY-17394). Cyclanoline chloride can be used for research related to bladder cancer .

HY-N0754

Eupalinolide A	Structural Classification Classification of Application Fields Melilotus albus Desr. Terpenoids Sesquiterpenes Plants Compositae Inflammation/Immunology Disease Research Fields Source Classification	YAP HSP Reactive Oxygen Species (ROS) ERK Autophagy Apoptosis Tyrosinase DNA/RNA Synthesis
Eupalinolide A is a Yes-associated protein (YAP) degrader and HSP70 inducer. Eupalinolide A inhibits osteogenic differentiation of tendon-derived stem cells (TDSCs). Eupalinolide A induces autophagy in hepatocellular carcinoma cells via activating the ROS/ERK signaling pathway. Eupalinolide A protects PAM212 cells from UVB-, Menadione (HY-B0332)-, or heat shock-induced apoptosis. Eupalinolide A alleviates trauma-induced heterotopic ossification (HO) of Achilles tendon and inhibits growth of MHCC97-L and HCCLM3 hepatocellular carcinoma xenograft tumors in mice. Eupalinolide A can be used for the study of traumatic heterotopic ossification of tendons and hepatocellular carcinoma .

HY-N2445

Flavokawain C 4 Publications Verification	Structural Classification Classification of Application Fields Piperaceae Plants Chalcones Flavonoids other families Phenols Polyphenols Piper methysticum G.Forst. Disease Research Fields Source Classification Cancer	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-N0475

Triptophenolide Hypolide; (+)-Triptophenolide	Structural Classification Monophenols Classification of Application Fields Terpenoids Celastraceae Other Diseases Phenols Diterpenoids Tripterygium wilfordii Hook. f. Plants Disease Research Fields Source Classification	Androgen Receptor Pyroptosis Caspase Bcl-2 Family Apoptosis
Triptophenolide (Hypolide) is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC₅₀ of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer .

HY-N1510

Kaempferol 3-O-gentiobioside	Flavonols Structural Classification Flavonoids Sauropus spatulifolius Beille Classification of Application Fields Phenols Polyphenols Metabolic Disease Euphorbiaceae Plants Disease Research Fields Source Classification	Glycosidase Notch Toll-like Receptor (TLR) NF-κB Mucin Reactive Oxygen Species (ROS) Bacterial TGF-beta/Smad Anaplastic lymphoma kinase (ALK)
Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a K_a value of 57 µM against human NOTCH1 and an IC₅₀ value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the TGF-β/ALK5/Smad signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma . It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer .

HY-N3389

Licoisoflavone A 2 Publications Verification	Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones Source Classification	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .

HY-N7694

Isotoosendanin 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Melia toosendan Sieb. et Zucc. Plants Meliaceae Inflammation/Immunology Disease Research Fields Source Classification	TGF-β Receptor JAK STAT Apoptosis
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-N15497

Terpestacin	Animals Terpenoids Sesquiterpenes Source Classification	Reactive Oxygen Species (ROS) HIF/HIF Prolyl-Hydroxylase
Terpestacin is found in Phoma exigua var. heteromorpha. Terpestacin binds to UQCRB to inhibit the production of mitochondrial ROS and HIF-1α. Terpestacin inhibits tumor angiogenesis in the FM3A breast cancer cell xenograft mouse model. Terpestacin has antitumor activity and phytotoxicity .

HY-N6651

Isocryptotanshinone	Quinones Structural Classification Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Source Classification Cancer	STAT Phosphatase Apoptosis Autophagy p38 MAPK EGFR JAK Bcl-2 Family Survivin Akt mTOR PARP Caspase Atg8/LC3 CDK
Isocryptotanshinone is a dual STAT3 and PTP1B (IC₅₀ = 56.1 μM) inhibitor. Isocryptotanshinone inhibits STAT3 by binding to the STAT3 SH2 domain to block phosphorylation and nuclear translocation ^[1][2]. Isocryptotanshinone exerts its anti-proliferative effect via the induction of cell cycle arrest, apoptosis, and pro-death autophagy, through the regulation of STAT3, AKT/mTOR and MAPK signaling pathways. Isocryptotanshinone suppresses the xenograft gastric cancer (GC) tumor growth in BALB/c nude mice. Isocryptotanshinone can be used for cancer research, such as lung cancer, breast cancer and GC .

HY-N13009

MO-2097	Phenols Polyphenols Morus alba L. Plants Moraceae Source Classification	Raf HIF/HIF Prolyl-Hydroxylase ERK MEK Reactive Oxygen Species (ROS) Apoptosis Caspase
MO-2097 is a RAF-1/HIF-1α inhibitor. MO-2097 induces RAF-1 destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the RAF/MEK/ERK signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer .

HY-B0199R

Mycophenolate Mofetil (Standard) RS 61443 (Standard); TM-MMF (Standard)	Structural Classification Monophenols Phenols Endogenous metabolite Source Classification	Reference Standards Interleukin Related
Mycophenolate Mofetil (Standard) is the analytical standard of Mycophenolate Mofetil. This product is intended for research and analytical applications. Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .

HY-N6237

Aspulvinone O	Infection Structural Classification Microorganisms Classification of Application Fields Phenols Polyphenols Disease Research Fields Source Classification	Aminotransferases (Transaminases) Apoptosis
Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces NADPH production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models .

HY-125135

(-)-β-Peltatin β-Peltatin	Structural Classification Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Source Classification	Apoptosis Bcl-2 Family Caspase PARP
(-)-β-Peltatin is an aryltetrahydronaphthalene lignan. (-)-β-Peltatin exhibits antitumor activity and cytotoxicity against pancreatic cancer cells. (-)-β-Peltatin induces G2/M cell cycle arrest and apoptosis in pancreatic cancer cells. (-)-β-Peltatin inhibits the growth of subcutaneous xenografts of pancreatic cancer cells in nude mice. (-)-β-Peltatin can be used in pancreatic cancer-related research .

HY-135217

Apiole	Natural Products Umbelliferae Plants Petroselinum crispum (Mill.) Fuss Source Classification	Apoptosis
Apiole is an anti-tumor agent that induces apoptosis and inhibits human colon cancer cells by inducing G0/G1 cell cycle arrest. Apiole also significantly inhibited colon tumor development in an in vivo mouse xenograft model .

HY-139104

Thailanstatin D	Alkaloids Microorganisms Classification of Application Fields Disease Research Fields Cancer Source Classification	DNA/RNA Synthesis Apoptosis
Thailanstatin D, an analogue of Thailanstatin A, is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3' splice site. Thailanstatin D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis .

HY-N12044

Asparanin A	Structural Classification Liliaceae Plants Steroids Source Classification Asparagus officinalis L.	Apoptosis
Asparanin A is an apoptosis inducer with anticancer activity. Asparanin A induces cell cycle arrest in the G0/G1 phase through mitochondria and PI3K/AKT signaling pathways, inhibiting cancer cell growth. Asparanin A also demonstrated in vivo efficacy in a mouse xenograft model of Ishikawa endometrial carcinoma, significantly inhibiting tumor growth .

HY-N4308

Hexamethylquercetagetin Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone	Flavonols Structural Classification Flavonoids other families Classification of Application Fields Plants Disease Research Fields Source Classification Cancer	NF-κB IKK Bcl-2 Family
Hexamethylquercetagetin (Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone) is an orally active NF-κB inhibitor. Hexamethylquercetagetin inhibits NF-κB-derived luciferase activity, reduces phosphorylated p65 and IκBα, Cyclin D1, Bcl-2 and blocks TNFα-induced NF-κB activation. Hexamethylquercetagetin inhibits survival and proliferation of cervical carcinoma cells. Hexamethylquercetagetin suppresses tumor volume and weight in BALB/c nude mouse xenograft models of cervical carcinoma. Hexamethylquercetagetin can be used for the research of cancer, such as cervical carcinoma .

HY-N2199

Sotetsuflavone	Structural Classification Flavonoids Classification of Application Fields Phenols Polyphenols Selaginellaceae Plants Biflavones Selaginella tamariscina (P. Beauv.) Spring Disease Research Fields Source Classification Cancer	Apoptosis Autophagy PI3K JNK mTOR p38 MAPK CDK MMP TGF-beta/Smad STAT β-catenin Reactive Oxygen Species (ROS) Bcl-2 Family Caspase
Sotetsuflavone is a flavonoid that can be isolated from Cycas revolute. Sotetsuflavone inhibits phosphorylation of PI3K, Akt, mTOR, JNK, and p38 MAPK; modulates expression of Cyclin D1, CDK4, Bcl-2, Bax, cleaved caspases 3/9, MMP-9, TGF-β, STAT3, and β-catenin. Sotetsuflavone induces G₀/G₁ cell cycle arrest, apoptosis, autophagy, and intracellular ROS elevation, inhibits cancer cell proliferation. Sotetsuflavone inhibits tumor growth in mouse tumor xenograft models. Sotetsuflavone can be used for the research of non-small cell lung cancer and Crohn’s disease .

HY-N6972R

Cepharanthine (Standard)	Structural Classification Alkaloids Stephania cepharantha Hayata Plants Isoquinoline Alkaloids Menispermaceae Stephania japonica (Thunb.) Miers	Autophagy Reference Standards SARS-CoV Cytochrome P450 Apoptosis Parasite
Cepharanthine (Standard) is the analytical standard of Cepharanthine. This product is intended for research and analytical applications. Cepharanthine is a natural product that can be isolated from the plant Stephania?cephalantha?Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46?μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

HY-N5166

Ardeemin (-)-Ardeemin	Alkaloids Microorganisms Indole Alkaloids Source Classification	P-glycoprotein
Ardeemin ((-)-Ardeemin) binds to the P-glycoprotein, preventing anticancer agent from being pumped out of cells. Ardeemin reverses the multidrug resistance phenotype of tumor cells and increases the sensitivity of tumor cells to anticancer agent in mammary carcinoma xenografts .

HY-135217R

Apiole (Standard)	Structural Classification Natural Products Umbelliferae Plants Petroselinum crispum (Mill.) Fuss Source Classification	Apoptosis Reference Standards
Apiole (Standard) is the analytical standard of Apiole. This product is intended for research and analytical applications. Apiole is an anti-tumor agent that induces apoptosis and inhibits human colon cancer cells by inducing G0/G1 cell cycle arrest. Apiole also significantly inhibited colon tumor development in an in vivo mouse xenograft model .

HY-N0421R

Cinobufagin (Standard) Cinobufagine (Standard)	Structural Classification Animals Steroids Source Classification	Reference Standards Apoptosis
Cinobufagin (Standard) is the analytical standard of Cinobufagin. This product is intended for research and analytical applications. Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .

HY-N9174

5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone	Flavonoids Flavones Plants Moraceae Broussonetia papyrifera (Linnaeus) L'Heritier ex Ventenat Source Classification	Others
5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone is a natural product that can be extracted from B. papyrifera. 5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone has potent anti-proliferation effects on ER-positive breast cancer cells, with an IC₅₀ value of 4.41 μM for MCF-7 cells. 5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone also reduces the tumor growth in the BCAP-37 xenograft .

HY-N0475R

Triptophenolide (Standard) Hypolide (Standard); (+)-Triptophenolide (Standard)	Structural Classification Monophenols Terpenoids Celastraceae Phenols Diterpenoids Tripterygium wilfordii Hook. f. Plants Source Classification	Reference Standards Androgen Receptor Pyroptosis Caspase Bcl-2 Family Apoptosis
Triptophenolide (Standard) (Hypolide) is the analytical standard of Triptophenolide (HY-N0475). This product is intended for research and analytical applications. Triptophenolide is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC₅₀ of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer .

HY-N14093

Aspulvinone H	Structural Classification Microorganisms Phenols Polyphenols Source Classification	Cholinesterase (ChE) Lipase Reactive Oxygen Species (ROS) Apoptosis Bacterial
Aspulvinone H is an orally active inhibitor of AChE, pancreatic lipase, glutamic-oxaloacetic transaminase 1, and α-glucosidase, with IC₅₀ values of 25.95 μM, 47.06 μM, 5.91/6.91 μM, and 4.6 μM, respectively. It has a K_a of 2.14 μM against GOT1 and a K_i of 6.58 μM against α-glucosidase. Aspulvinone H inhibits cancer cell proliferation, interferes with glutamine metabolism, elevates ROS levels, and induces cell apoptosis and S-phase arrest. Aspulvinone H exhibits antibacterial activity against Staphylococcus aureus. Aspulvinone H inhibits the growth of pancreatic ductal adenocarcinoma xenografts. Aspulvinone H reduces postprandial blood glucose in mice. Aspulvinone H can be used in research related to pancreatic ductal adenocarcinoma, diabetes, and Staphylococcus aureus infection .

Cat. No.	상품명	Chemical Structure

HY-B0199S

Mycophenolate Mofetil-d4

Mycophenolate Mofetil-d₄ is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-179219S

RTx-303
RTx-303 is an orally active, selective DNA polymerase θ (Polθ) inhibitor (IC₅₀ = 5.1 nM). RTx-303 exhibits significantly high cellular potency and strongly potentiates PARPi in BRCA1/2 mutant cells and patient-derived xenograft models. RTx-303 can be used for the study of BRCA2-mutated breast cancer .

HY-175318S

p53 Activator 15
p53 Activator 15 is an orally active p53 Y220C activator. p53 Activator 15 enhances the DNA binding of p53 Y220C (SC₅₀ = 0.58 nM) and significantly inhibits NUGC-3 cell proliferation. p53 Activator 15 effectively inhibits tumor growth in NUGC-3 xenograft mouse and rat models. p53 Activator 15 can be used to study gastric cancer .

HY-B0199AS

Mycophenolate Mofetil-d4 hydrochloride

Mycophenolate Mofetil-d₄ hydrochloride is deuterated labeled Mycophenolate mofetil hydrochloride (HY-B0199A). Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .

HY-W747797

Cinobufagine-d3
Cinobufagine-d₃ is the deuterium labeled Cinobufagin (HY-N0421). Cinobufagin is an anticancer agent that can be secreted by the Asiatic toad Bufo gargarizans. Cinobufagin induces the cell cycle arrests in the G1 phase or G2/M phase, leading to apoptosis in cancer cells. Cinobufagin inhibits tumor growth in melanoma and glioblastoma multiforme xenograft mouse models .

Cat. No.	상품명		Classification

HY-145483

KT-474 1 Publications Verification KYM-001; PROTAC IRAK4 degrader-7		PROTAC Synthesis
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups .

HY-173637

AZD0022		Alkynes
AZD0022 is a selective and orally active KRAS ^G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .

HY-148813

AK-2292 2 Publications Verification		PROTAC Synthesis
AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC₅₀ of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139659

ARD-61		PROTAC Synthesis
ARD-61 is a highly potent, effective and specific PROTAC androgen receptor (AR) degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines. ARD-61 induces apoptosis and effectively induces tumor growth inhibition in the MDA-MB-453 xenograft model in mice . ARD-61 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-143904

PROTAC TTK degrader-1		PROTAC Synthesis
PROTAC TTK degrader-1 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 1.7 and 5.8 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-1 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-14375

CB 300919		Alkynes
CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC₅₀ value of 2 nM in human CH1 ovarian tumor xenograft . CB 300919 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-120569

NC-001		Azide
NC-001 is a selective apoptosis inducer targeting renal proximal tubular cells and renal cancer cells. NC-001 inhibits tumor growth in clear cell renal cell carcinoma (CCRCC) xenograft models. NC-001 is promising for research of metastatic renal cell carcinoma .

HY-143905

PROTAC TTK degrader-2		PROTAC Synthesis
PROTAC TTK degrader-2 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 3.1 and 12.4 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-2 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-178370

Ferroptosis inducer-12		Alkynes
Ferroptosis inducer-12 is a potent and selective ferroptosis inducer. Ferroptosis inducer-12 exhibits potent antiproliferative activity against HT1080 and OS-RC-2, with IC₅₀ values of 3 nM and 5 nM, respectively. Ferroptosis inducer-12 strongly inhibits GPX4 enzymatic activity, induces intracellular ROS and elevates intracellular Fe ²⁺ levels in OS-RC-2 cells. Ferroptosis inducer-12 significantly inhibits tumor growth in BALB/c nude mice bearing OS-RC-2 xenografts. Ferroptosis inducer-12 can be used for the study of cancer .

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

HY-175201

pro-FTY		Azide
pro-FTY, a FTY720 (HY-12005) anticancer prodrug, is a sphingosine-1-phosphate (S1P) (HY-108496) inhibitor. pro-FTY specifically inhibits S1P signaling in cancer cells using a drug delivery system (DDS) that reacts with acrolein. pro-FTY significantly inhibits the survival of breast cancer cells, including multidrug-resistant cells and its organoids resistant to Paclitaxel (HY-B0015) or Doxorubicin (HY-15142A). pro-FTY potently suppresses tumor growth in 4T1 cells or organoids xenograft tumors mice model while avoiding lymphocytopenia .

HY-181849

MS2928		Alkynes
MS2928 is a selective SETD8 inhibitor with an IC₅₀ of 0.14 μM against SETD8 methyltransferase activity. MS2928 reduces cellular H4K20_me1 levels and inhibits proliferation of SETD8-overexpressing multiple myeloma cells. MS2928 inhibits tumor growth in xenograft mouse models of SETD8-overexpressing multiple myeloma. MS2928 can be used for the study of SETD8 biological functions and multiple myeloma .

HY-180200

RNK08954		Alkynes
RNK08954 is an orally active KRAS^G12D inhibitor with a K_d of 0.0395 nM. RNK08954 selectively binds the inactive GDP-bound KRAS^G12D form, suppresses downstream KRAS-mediated signaling pathways p-ERK1/2 experssion. RNK08954 inhibits KRAS^G12D-mutant cell proliferation, induces G0-G1 cell cycle arrest, and inhibits tumor growth in mouse xenograft models. RNK08954 can be used for the research of non-small cell lung cancer, pancreatic ductal adenocarcinoma .

HY-179404

KRASG12C IN-18		Alkynes
KRASG12C IN-18 is an orally active covalent KRAS ^G12C inhibitor that achieves complete covalent engagement of KRAS ^G12C in both GDP- and GMPPNP-bound states and displays strong antiproliferative activity against KRAS ^G12C and resistance-associated variants, including KRAS ^G12C/R68S, with low-nanomolar IC₅₀ values. KRASG12C IN-18 exhibits marked in vivo efficacy in KRAS ^G12C-driven solid tumor and KRAS ^G12C/R68S xenograft models and can be used for colorectal cancer research .

Cat. No.	상품명		Classification

HY-153834

GTI 2040		Aptamers
GTI-2040, a 20-mer phosphorothioate oligonucleotide, was designed to hybridize to the mRNA sequence of human ribonucleotide reductase R2. GTI-2040 has been shown to inhibit human cancer cell proliferation by downregulation of R2 expression in vitro and to significantly inhibit tumor growth in xenograft models of human cancer in mice.

HY-158829

SSOe26 sodium		Antisense Oligonucleotides
SSOe26 sodium is a 15mer antisense oligonucleotide targeting?HER4. SSOe26 sodium induces exon 26 skipping, leading to the generation of a novel mRNA transcript that excludes exon 26 (CYT2 isoform). SSOe26 sodium decreases tumour growth in mouse xenografts.

HY-164185

P12FR2 sodium		Aptamers
P12FR2 sodium is an aptamer targeting human pancreatic adenocarcinoma up-regulated factor (PAUF). P12FR2 specifically binds to human PAUF with an estimated apparent KD of 77 nM. P12FR2 inhibits PAUF-induced PANC-1 cell migration and pancreatic cancer xenograft growth.

HY-153834A

GTI 2040 sodium		Aptamers
GTI-2040 sodium, a 20-mer phosphorothioate oligonucleotide, was designed to hybridize to the mRNA sequence of human ribonucleotide reductase R2. GTI-2040 sodium has been shown to inhibit human cancer cell proliferation by downregulation of R2 expression in vitro and to significantly inhibit tumor growth in xenograft models of human cancer in mice.

HY-158830

MDM4-targeting ASO sodium		Antisense Oligonucleotides
MDM4-targeting ASO sodium is a 25mer antisense oligonucleotide targeting MDM4. MDM4-targeting ASO sodium induced exon 6 skipping, leading to nonsense-mediated decay of the mRNA transcript that excludes exon-6. In multiple human melanoma cell lines and in melanoma patient-derived xenograft (PDX) mouse models, MDM4-targeting ASO-mediated skipping of exon 6 decreased MDM4 abundance, inhibited melanoma growth, and enhanced sensitivity to MAPK-targeting therapeutics.

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-159642G

Dabogratinib TYRA-300	FGFR ERK	Metabolic Disease Cancer
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

xenograft.

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products